Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Zylox-Tonbridge Medical Technology Co Buyback Yield %?
Zylox-Tonbridge Medical Technology CoFRA:818 -2.80%76 Buyback Yield % is 1.88 as of Aug. 17, 2026, which is 25% above its 10-year median of 1.50. GuruFocus rates FRA:818 with a GF Score™ of 76/100 and a GF Value™ of €3.72 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 341 Medical Devices & Instruments companies, Zylox-Tonbridge Medical Technology Co ranks better than 84.75% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zylox-Tonbridge Medical Technology Co Buyback Yield % Chart
FRA:818 vs ABT, SYK, MDT: Buyback Yield % Comparison
For the Medical Devices subindustry, Zylox-Tonbridge Medical Technology Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zylox-Tonbridge Medical Technology Co Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zylox-Tonbridge Medical Technology Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Zylox-Tonbridge Medical Technology Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zylox-Tonbridge Medical Technology Co (FRA:818) has a Buyback Yield % of 1.88 as of Aug. 17, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Zylox-Tonbridge Medical Technology Co and its competitors. This is 25% above median its historical median of 1.50. According to the industry distribution chart, Zylox-Tonbridge Medical Technology Co ranks #52 out of 341 companies in the Medical Devices & Instruments industry, placing it in the top 15.2%.
Is Zylox-Tonbridge Medical Technology Co's Buyback Yield % too high?
Zylox-Tonbridge Medical Technology Co's current Buyback Yield % of 1.88 is 25% above median its 10-year median of 1.50. Based on the distribution chart, Zylox-Tonbridge Medical Technology Co ranks #52 out of 341 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Zylox-Tonbridge Medical Technology Co has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zylox-Tonbridge Medical Technology Co's Buyback Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zylox-Tonbridge Medical Technology Co ranks #52 out of 341 companies for Buyback Yield %. This places Zylox-Tonbridge Medical Technology Co in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Zylox-Tonbridge Medical Technology Co and its competitors. Zylox-Tonbridge Medical Technology Co's current Buyback Yield % is 1.88, which is 25% above median its own 10-year median of 1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zylox-Tonbridge Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co (FRA:818) is currently considered Significantly Undervalued. The stock's GF Value™ is €3.72, compared to a current price of €2.08 — trading 44.1% below its estimated fair value. The current Buyback Yield % is 1.88, which is 25% above median its 10-year median of 1.50. Zylox-Tonbridge Medical Technology Co's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Zylox-Tonbridge Medical Technology Co (FRA:818), the current Buyback Yield % is 1.88 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zylox-Tonbridge Medical Technology Co (FRA:818) Overvalued in 2026?
Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co stock appears to be undervalued.
The current stock price of €2.08 is trading 44.1% below its estimated GF Value™ of €3.72.
GuruFocus considers Zylox-Tonbridge Medical Technology Co to be Significantly Undervalued.
Key valuation signals for FRA:818:
Buyback Yield %: 1.88 (25% above median its 10-year median of 1.50)
GF Value™: €3.72 vs. price of €2.08 (44.1% below fair value)
No single metric tells the full story. See the FRA:818 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's products include Thrombite Clot Retriever Device (Thrombite CRD), Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB), and others. The company derives majority of its revenue from PRC.
76GF Score
Get the complete analysis for FRA:818
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:818 has been successfully added to your 
